Your browser doesn't support javascript.
Clash of the titans: interferons and SARS-CoV-2.
Jouvenet, Nolwenn; Goujon, Caroline; Banerjee, Arinjay.
  • Jouvenet N; Institut Pasteur, Université de Paris, CNRS UMR3569, Virus Sensing and Signaling Unit, Paris, France. Electronic address: nolwenn.jouvenet@pasteur.fr.
  • Goujon C; IRIM, CNRS, Montpellier University, Montpellier 34090, France. Electronic address: caroline.goujon@irim.cnrs.fr.
  • Banerjee A; Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada; Department of Veterinary Microbiology, University of Saskatchewan, Saskatoon, SK S7N 5B4, Canada; Department of Biology, University of Waterloo, Waterloo, ON N2L 3G1, Canada. Electronic address: arinjay.banerjee@usask.ca.
Trends Immunol ; 42(12): 1069-1072, 2021 12.
Article in English | MEDLINE | ID: covidwho-1466428
ABSTRACT
Interferons are our first line of defense against invading viruses. However, viruses encode effector proteins that can modulate human interferon responses. In this forum article, we highlight important discoveries and discuss outstanding questions that will enable us to better understand the nuances of this evolutionary battle between interferons and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: English Journal: Trends Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: English Journal: Trends Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article